Premium
In utero transplantation of wild‐type fetal liver cells rescues factor X‐deficient mice from fatal neonatal bleeding diatheses
Author(s) -
Rosen E. D.,
Cornelissen I.,
Liang Z.,
Zollman A.,
Casad M.,
Roahrig J.,
Suckow M.,
Castellino F. J.
Publication year - 2003
Publication title -
journal of thrombosis and haemostasis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.947
H-Index - 178
eISSN - 1538-7836
pISSN - 1538-7933
DOI - 10.1046/j.1538-7836.2003.00030.x
Subject(s) - in utero , liver transplantation , fetus , medicine , transplantation , pregnancy , biology , genetics
Summary. Factor X (FX)‐deficient embryos suffer partial embryonic lethality with approximately 30% of the embryos arresting at midgestation. The remaining animals survive to term but die perinatally mainly from abdominal or intracranial hemorrhage. We have rescued FX‐deficient mice by transplanting fetal liver cells from FX+/+, Rosa26 fetuses into midgestation embryos derived from FX+/− heterozygous crosses. FX−/− embryos were born at the expected frequency and approximately 50% of the FX−/− neonates survived longer than 4 months. FX−/− embryos receiving saline injections that survived to term died perinatally similar to untreated FX‐deficient mice. The plasma levels of FX in the rescued 16‐week‐old FX−/− mice were approximately 1–6% of wild‐type levels. β‐Galactosidase‐staining cells derived from the donor Rosa26 fetal liver cells were detected in 47% of the livers of adult mice. In addition, donor‐derived cells were also recovered in the bone marrow, spleen, lung, and occasionally in the brain and testis. These results suggest that in utero cell transplantation could be an effective therapeutic strategy to treat pathologies resulting from the deficiency of hepatic‐expressed factors.